All Stories

  1. Protocolo de tratamiento del edema macular quístico asociado a retinosis pigmentaria y otras distrofias hereditarias de la retina
  2. Ala®sil chemical characterization and toxicity evaluation: an example of the need for the Medical Device Regulation 2017/745
  3. A minimum specification dataset for liquid ocular endotamponades: recommendations by a European expert panel
  4. Intravitreal allogeneic mesenchymal stem cells: a non-randomized phase II clinical trial for acute non-arteritic optic neuropathy
  5. INTRAOCULAR EMULSION OF SILICONE OIL (ITEMS) GRADING SYSTEM
  6. Evaluación de signos tomográficos no exudativos en casos de degeneración macular asociada a la edad de tipo exudativo
  7. Impact of COVID-19 Confinement on Quality of Life of Patients with Age-Related Macular Degeneration: A Two-Wave Panel Study
  8. Does PLEX® Elite 9000 OCT Identify and Characterize Most Posterior Pole Lesions in Highly Myopic Patients?
  9. Gene editing strategy for development of an inherited retinal dystrophy model based on iPSC‐derived photoreceptors with mutation in the PROM1 gene
  10. Neuroprotection in ophthalmology. Targets in the most frequent diseases. A clinician's point of view
  11. Hair cortisol level as a molecular biomarker in retinitis pigmentosa patients
  12. Pathophysiology of Age-Related Macular Degeneration. Implications for Treatment
  13. Modifiable Determinants of Satisfaction with Intravitreal Treatment in Patients with Neovascular Age-Related Macular Degeneration
  14. Long-term visual pathway alterations after elemental mercury poisoning: report of a series of 29 cases
  15. Cell Replacement Therapy for Retinal and Optic Nerve Diseases: Cell Sources, Clinical Trials and Challenges
  16. Monochromatic higher order aberrations in highly myopic eyes with Staphyloma
  17. Cell Therapy Replacement for Retinal and Optic Nerve Diseases: Cell Sources, Clinical Trials and Challenges
  18. Phenotypic Differences in a PRPH2 Mutation in Members of the Same Family Assessed with OCT and OCTA
  19. Descriptive Study of a Cohort of 488 Patients with Inherited Retinal Dystrophies
  20. Intraocular toxicity caused by MEROCTANE perfluorocarbon liquid
  21. Silicone microbubbles after anti‐vascular endothelial growth factor injections in patients with wet age‐related macular degeneration: incidence, quantification and secondary optical coherence tomography artfacts
  22. Visual Pathway Alterations after Severe Acute Occupational Elemental Mercury Poisoning: Report of a Series of 29 Cases
  23. Early Detection of Incipient Retinal Pigment Epithelium Atrophy Overlying Drusen with Fundus Autofluorescence vs. Spectral Domain Optical Coherence Tomography
  24. Matrix Metalloproteinases in Age-Related Macular Degeneration (AMD)
  25. PRPH2-Related Retinal Diseases: Broadening the Clinical Spectrum and Describing a New Mutation
  26. Progression of myopic maculopathy in a Caucasian cohort of highly myopic patients with long follow-up: a multistate analysis
  27. Intravitreal stem cell paracrine properties as a potential neuroprotective therapy for retinal photoreceptor neurodegenerative diseases
  28. Chemical compounds causing severe acute toxicity in heavy liquids used for intraocular surgery
  29. Reliability of colour perimetry to assess macular pigment optical density in age-related macular degeneration
  30. Chemical Considerations Regarding the H-Value Methodology and Its Relation With Toxicity Determination
  31. Development and evaluation of a head-mounted display system based on stereoscopic images and depth algorithms for patients with visual impairment
  32. Diagnostic and Therapeutic Challenges
  33. Acute retinal toxicity associated with a mixture of perfluorooctane and perfluorohexyloctane: failure of another indirect cytotoxicity analysis
  34. Comparison between direct contact and extract exposure methods for PFO cytotoxicity evaluation
  35. Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab
  36. ACUTE RETINAL DAMAGE AFTER USING A TOXIC PERFLUORO-OCTANE FOR VITREO-RETINAL SURGERY
  37. El problema de la toxicidad aguda de algunos perfluoro-octanos
  38. Effectiveness and safety of nutritional supplements in the treatment of hereditary retinal dystrophies: a systematic review
  39. Clinical Characterization and Frequency of Observation of Hereditary Retinal Diseases: Multicentric Study in Panama in 2012-2013
  40. CopyMean: A new method to predict monotone missing values in longitudinal studies
  41. Erratum
  42. Patient participation in the development of a clinical guideline for inherited retinal dystrophies
  43. Predictors of Macular Atrophy Detected by Fundus Autofluorescence in Patients With Neovascular Age-Related Macular Degeneration After Long-Term Ranibizumab Treatment
  44. X-Linked retinoschisis associated to a novel intragenic microdeletion: case report
  45. Control of disability glare by means of electrochromic filtering glasses: A pilot study
  46. Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT)
  47. Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases
  48. Progression of Retinal Pigment Epithelial Atrophy in Antiangiogenic Therapy of Neovascular Age-Related Macular Degeneration
  49. BAX and BCL‐2 polymorphisms, as predictors of proliferative vitreoretinopathy development in patients suffering retinal detachment: the Retina 4 project
  50. Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
  51. Loss of Visual Acuity after Successful Surgery for Macula-On Rhegmatogenous Retinal Detachment in a Prospective Multicentre Study
  52. Vision-Threatening Lesions Developing with Longer-Term Follow-up after Treatment of Neovascular Age-Related Macular Degeneration
  53. Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain
  54. Quantitative SD-OCT Imaging Biomarkers as Indicators of Age-Related Macular Degeneration Progression
  55. Predicting proliferative vitreoretinopathy: temporal and external validation of models based on genetic and clinical variables
  56. Management of significant reactivation of old disciform scars in wet Age-Related Macular Degeneration
  57. Growth of Geographic Atrophy on Fundus Autofluorescence and Polymorphisms ofCFH,CFB,C3,FHR1-3, andARMS2in Age-Related Macular Degeneration
  58. Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
  59. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
  60. Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
  61. The T309G MDM2 Gene Polymorphism Is a Novel Risk Factor for Proliferative Vitreoretinopathy
  62. Prediction of Age-related Macular Degeneration in the General Population
  63. Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
  64. EXTERNAL VALIDATION OF EXISTING FORMULAS TO PREDICT THE RISK OF DEVELOPING PROLIFERATIVE VITREORETINOPATHY
  65. Evolución clínica de pacientes con degeneración macular asociada a la edad de tipo exudativo-hemorrágico tratados con ranibizumab. Estudio Eye2Eye
  66. General Practitioners´ knowledge gaps regarding Age Related Macular Degeneration and effectiveness of their e-learning training
  67. A Genetic Case-Control Study Confirms the Implication ofSMAD7andTNF Locusin the Development of Proliferative Vitreoretinopathy
  68. The p53 Codon 72 Polymorphism (rs1042522) Is Associated with Proliferative Vitreoretinopathy
  69. Retinal Pigment Epithelial Cell Loss Assessed by Fundus Autofluorescence Imaging in Neovascular Age-related Macular Degeneration
  70. Ocular Pain After Intravitreal Injection
  71. A New Manual Retinal Thickness Measurement Protocol to Evaluate High Myopia Patients
  72. Patient-Reported Outcomes in Spanish Patients Diagnosed with Bilateral Age-Related Macular Degeneration
  73. Autofluorescence Images with Carl Zeiss versus Topcon Eye Fundus Camera: A Comparative Study
  74. Therapies for Neovascular Age-Related Macular Degeneration: Current Approaches and Pharmacologic Agents in Development
  75. Variations in Functional and Anatomical Outcomes and in Proliferative Vitreoretinopathy Rate along a Prospective Collaborative Study on Primary Rhegmatogenous Retinal Detachments: The Retina 1 Project—Report 4
  76. E‐learning strategies to improve general practitioners’ knowledge of age‐related macular degeneration
  77. Relevance of Complement Factor H–Related 1 (CFHR1) Genotypes in Age-Related Macular Degeneration
  78. Retinal Pigment Epithelium Tears in Age-Related Macular Degeneration Treated with Antiangiogenic Drugs: A Controlled Study with Long Follow-Up
  79. Pathology Associated with Optical Coherence Tomography Macular Bending due to either Dome-Shaped Macula or Inferior Staphyloma in Myopic Patients
  80. Sjogren-Larsson Syndrome
  81. Sjögren-Larsson Syndrome
  82. A propensity score matching application: indications and results of adding scleral buckle to vitrectomy: The Retina 1 Project: Report 3
  83. Training and professional profile of retinologists in Spain: Retina 2 project, Report 4
  84. Genética y DMAE: del laboratorio a la consulta
  85. A Strong Genetic Association between the Tumor Necrosis Factor Locus and Proliferative Vitreoretinopathy: The Retina 4 Project
  86. Genetic association study of age-related macular degeneration in the Spanish population
  87. Benign Fleck Retina
  88. Diagnostic and Therapeutic Challenges
  89. PRPH2 (Peripherin/RDS) Mutations Associated with Different Macular Dystrophies in a Spanish Population: A New Mutation
  90. Formación y actividad clínica de los retinólogos en España: un primer acercamiento: Proyecto retina 2. Análisis descriptivo
  91. DIAGNOSTIC AND THERAPEUTIC CHALLENGES
  92. Surgical outcomes for primary rhegmatogenous retinal detachments in phakic and pseudophakic patients: the Retina 1 Project--report 2
  93. Non-complicated retinal detachment management: variations in 4 years. Retina 1 project; report 1
  94. Diagnostic and Therapeutic Challenges
  95. OCT FINDINGS IN TORPEDO MACULOPATHY
  96. El impacto de la Ley de Dependencia en los pacientes con baja visión
  97. Photodynamic Therapy for Subfoveal and Juxtafoveal Choroidal Neovascularization Associated with Punctate Inner Choroidopathy
  98. Complement Factor H
  99. Atypical Myopic Retinoschisis
  100. Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization
  101. Burden of illness of bilateral neovascular age-related macular degeneration in Spain
  102. Intraretinal Immunohistochemistry Findings in Proliferative Vitreoretinopathy with Retinal Shortening
  103. Reading comparative study: Electronic vs. conventional devices
  104. Monocromatismo de conos azules ligado a X: Una familia afecta
  105. Complicaciones corneales epiteliales de las vitrectomías: estudio retrospectivo
  106. Acortamiento retinado: la forma más grave de la vitreorretinopatía proliferante (VRP)
  107. Roturas retinianas iatrogénicas en las vitrectomías: estudio retrospectivo
  108. Analysis ofABCA4in mixed Spanish families segregating different retinal dystrophies
  109. Fundus autofluorescence in patients with age-related macular degeneration and high risk of visual loss11Commercial interests: None.
  110. Pharmacokinetics of 0.5 mg of a Single and a Multiple Dose of Intravitreal Vancomycin in Infected Rabbit Eyes
  111. Further Evidence for an Association of ABCR Alleles with Age-Related Macular Degeneration
  112. Sjo ̈gren-Larsson syndrome
  113. Pharmacokinetics of Intravitreal Vancomycin in Normal and Infected Rabbit Eyes
  114. High-performance liquid chromatographic determination of vancomycin in rabbit serum, vitreous and aqueous humour after intravitreal injection of the drug
  115. New Electro-Optic and Display Technology for Visually Disabled People